Cardiovascular Research

E-cigarette or Vaping Product Use-Associated Lung Injury Produced in an Animal Model From Electronic Cigarette Vapor Exposure Wi

Authors: Michael T Kleinman|||Rebecca Johnson Arechavala|||David Herman|||Jianru Shi|||Irene Hasen|||Amanda Ting|||Wangde Dai|||Juan Carreno|||Jesus Chavez|||Lifu Zhao|||Robert A Kloner

Affiliations: + Expand

Abstract

E-cigarette or vaping product use-associated lung injury was recognized in the United States in the summer of 2019 and is typified by acute respiratory distress, shortness of breath, chest pain, cough, and fever, associated with vaping. It can mimic many of the manifestations of coronavirus disease 2019 (COVID-19). Some investigators have suggested that E-cigarette or vaping product use-associated lung injury was due to tetrahydrocannabinol or vitamin E acetate oil mixed with the electronic cigarette liquid. In experimental rodent studies initially designed to study the effect of electronic cigarette use on the cardiovascular system, we observed an E-cigarette or vaping product use-associated lung injury-like condition that occurred acutely after use of a nichrome heating element at high power, without the use of tetrahydrocannabinol, vitamin E, or nicotine. Lung lesions included thickening of the alveolar wall with foci of inflammation, red blood cell congestion, obliteration of alveolar spaces, and pneumonitis in some cases; bronchi showed accumulation of fibrin, inflammatory cells, and mucus plugs. Electronic cigarette users should be cautioned about the potential danger of operating electronic cigarette units at high settings; the possibility that certain heating elements may be deleterious; and that E-cigarette or vaping product use-associated lung injury may not be dependent upon tetrahydrocannabinol, vitamin E, or nicotine.

---

Chemical List

E-Cigarette Vapor|||Oils|||Vitamin E|||Dronabinol

---

Reference List

Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde MW, Navon L, Hoots B, Salvatore PP, Elderbrook M, et al. Pulmonary illness related to E‐cigarette use in Illinois and Wisconsin—preliminary report. N Engl J Med. 2020;382:903–916.|||Butt YM, Smith ML, Tazelaar HD, Vaszar LT, Swanson KL, Cecchini MJ, Boland JM, Bois MC, Boyum JH, Froemming AT, et al. Pathology of vaping‐associated lung injury. N Engl J Med. 2019;381:1780–1781.|||Henry TS, Kanne JP, Kligerman SJ. Imaging of vaping‐associated lung disease. N Engl J Med. 2019;381:1486–1487.|||Hswen Y, Brownstein JS. Real‐time digital surveillance of vaping‐induced pulmonary disease. N Engl J Med. 2019;381:1778–1780.|||Borensztajn K, Bresser P, van der Loos C, Bot I, van den Blink B, den Bakker MA, Daalhuisen J, Groot AP, Peppelenbosch MP, von der Thüsen JH, et al. Protease‐activated receptor‐2 induces myofibroblast differentiation and tissue factor up‐regulation during bleomycin‐induced lung injury. Am J Pathol. 2010;177:2753–2764.|||Haddad C, Salman R, El‐Hellani A, Talih S, Shihadeh A, Saliba NA. Reactive oxygen species emissions from Supra‐and Sub‐Ohm electronic cigarettes. J Anal Toxicol. 2019;43:45–50.